

Preemptive policy: This is a P&T approved policy and can be used after the drug is FDA approved until it is superseded by an updated policy



Clinical Policy: Etranacogene Dezaparvovec (AMT-061)

Reference Number: CP.PHAR.580

Effective Date: **FDA Approval Date**

Last Review Date: 05.22

Line of Business: Commercial, HIM, Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Etranacogene dezaparvovec (Brand Name^{®/™}) is adeno-associated virus five (AAV5)-based gene therapy.

FDA Approved Indication(s) **[Pending]**

AMT-061 is proposed for the treatment of congenital hemophilia B.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that AMT-061 is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria*

**Criteria will mirror the clinical information from the prescribing information once FDA-approved*

A. Congenital Hemophilia B (must meet all):

1. Diagnosis of congenital hemophilia B (factor IX deficiency);*
 2. Prescribed by or in consultation with hematologist;
 3. Age \geq 18 years;*
 4. Member has severe or moderately severe hemophilia (defined as factor IX level of \leq 2%);*
 5. Member meets both of the following (a and b):*
 - a. Member has been adherent with use of a factor IX product* (e.g., Alprolix[®], Benefix[®], Idelvion[®], Ixinity[®], Rixubis[®]) for routine prophylaxis for at least 12 months as assessed and documented by prescriber;
 - b. Occurrence of at least one serious spontaneous bleeding event while on routine prophylaxis (see Appendix D);
- *Prior authorization may be required*
6. Member has been treated with factor IX product for a minimum of 150 exposure days (see Appendix D);*
 7. Member meets both of the following (a and b):*
 - a. No previous documented history of a detectable factor IX inhibitor;
 - b. Member has inhibitor level assay $<$ 0.6 Bethesda units (BU) within the last 12 months;
 8. Member has documentation of AAV5 neutralizing antibody titer $<$ 678;

9. Dose does not exceed 2×10^{13} gc per kg.*

Approval duration: 3 months (1 dose only)

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy*

**Criteria will mirror the clinical information from the prescribing information once FDA-approved*

A. Congenital Hemophilia B

1. Continued therapy will not be authorized as etranacogene dezaparvovec is indicated to be dosed one time only.

Approval duration: Not applicable

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

AAV: adeno-associated virus

BU: Bethesda units

ED: exposure day

FDA: Food and Drug Administration

gc per kg: genome copies per kilogram

Appendix B: Therapeutic Alternatives

Not applicable

Appendix C: Contraindications/Boxed Warnings [Pending]

- Contraindication(s): **pending**
- Boxed warning(s): **pending**

Appendix D: General Information

- Serious bleeding episodes include bleeds in the following site: intracranial, neck/throat, or gastrointestinal joints (hemarthrosis).
- Spontaneous bleed is defined as a bleeding episode that occurs without apparent cause and is not the result of trauma.
- Exposure day (ED): An ED is a day on which a person with hemophilia has been infused with factor concentrate to treat or prevent a bleed. The number of EDs consists only of those days on which factor was infused.
 - 150 EDs of cumulative treatment increases the likelihood of immunologic stability – a decreased risk of producing inhibitors. Patients rarely develop inhibitors after 150 EDs.

V. Dosage and Administration [Pending]

Indication	Dosing Regimen	Maximum Dose
Congenital hemophilia B*	Pending	2×10^{13} gc/kg*

VI. Product Availability [Pending]

Pending

VII. References

1. ClinicalTrials.gov. HOPE-B: Trial of AMT-061 in severe or moderately severe hemophilia b patients. Available at: <https://clinicaltrials.gov/ct2/show/NCT03569891>. Accessed March 10, 2022.
2. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020 Aug;26 Suppl 6:1-158.

3. Carcao M and Goudemand J. Inhibitors in hemophilia: A primer, 5th edition. World Federation of Hemophilia. Available at: <https://www1.wfh.org/publication/files/pdf-1122.pdf>.

Coding Implications **[Pending]**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
Pending	Pending

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created pre-emptively	04.05.22	05.22
Template changes applied to other diagnoses/indications.	09.19.22	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan

retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2022 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.